Open AccessBaseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment
Author(s) -
Jingtao Tong,
Yifei Mao,
Ziru Yang,
Qian Xu,
Zheng Zhao,
Hui Zhang,
Jingjing Wang,
Sandian Zhang,
Weibo Rong,
Lijun Zheng
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s304022
Subject(s) - medicine , proportional hazards model , oncology , response evaluation criteria in solid tumors , receiver operating characteristic , lung cancer , area under the curve , hazard ratio , univariate analysis , progression free survival , survival analysis , cancer , retrospective cohort study , logistic regression , gastroenterology , multivariate analysis , progressive disease , confidence interval , disease , chemotherapy
Although predictive markers of immune checkpoint inhibitor (ICI)-based treatments have been extensively studied, with the exception of programmed death ligand 1 (PD-L1), most are not widely used in the clinic due to poor effects or defective practicability. The aim of this study was to identify those patients with high baseline serum cholesterol who benefit from ICI-based treatments.